development of antibodies
Company profile
Ticker
INBX
Exchange
Website
CEO
Mark Paul Lappe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
824257312
INBX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
12 Mar 24
8-K
Other Events
12 Mar 24
PREM14A
Preliminary proxy related to merger
29 Feb 24
8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
DEFA14A
Additional proxy soliciting materials
6 Feb 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
8-K
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
23 Jan 24
8-K
Inhibrx Reports Third Quarter 2023 Financial Results
9 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
26 Mar 24
4
Kelly Deck
22 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Brendan P. Eckelman
15 Mar 24
4
Kelly Deck
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Brendan P. Eckelman
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 337.33 mm | 337.33 mm | 337.33 mm | 337.33 mm | 337.33 mm | 337.33 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.26 mm | 15.72 mm | 18.08 mm | 13.92 mm |
Cash used (since last report) | n/a | n/a | 103.21 mm | 94.00 mm | 108.10 mm | 83.25 mm |
Cash remaining | n/a | n/a | 234.12 mm | 243.33 mm | 229.22 mm | 254.08 mm |
Runway (months of cash) | n/a | n/a | 13.6 | 15.5 | 12.7 | 18.2 |
Institutional ownership, Q3 2023
82.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 110 |
Opened positions | 13 |
Closed positions | 10 |
Increased positions | 42 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 691.46 bn |
Total shares | 39.10 mm |
Total puts | 1.20 k |
Total calls | 2.90 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Viking Global Investors | 7.15 mm | $131.22 bn |
Ra Capital Management | 4.72 mm | $86.69 bn |
Perceptive Advisors | 4.26 mm | $78.10 bn |
BLK Blackrock | 2.54 mm | $46.60 bn |
Vanguard | 1.79 mm | $32.84 bn |
TCG Crossover Management | 1.75 mm | $32.12 bn |
STT State Street | 1.62 mm | $29.67 bn |
Woodline Partners | 1.52 mm | $27.98 bn |
FMR | 1.52 mm | $27.85 bn |
Capital Research Global Investors | 1.22 mm | $22.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Kelly Deck | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35 | 110 | 3.85 k | 18,020 |
21 Mar 24 | Kelly Deck | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.0882 | 3,113 | 109.23 k | 18,130 |
20 Mar 24 | Kelly Deck | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.0213 | 16,777 | 587.55 k | 21,243 |
13 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.3332 | 1,898 | 67.06 k | 9,177 |
13 Mar 24 | Kelly Deck | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.429 | 32,431 | 1.15 mm | 2,087 |
12 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.2503 | 4,152 | 146.36 k | 29,167 |
12 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.2547 | 19,898 | 701.50 k | 11,075 |
11 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.3339 | 6,681 | 236.07 k | 33,319 |
11 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.3004 | 6,877 | 242.76 k | 30,973 |
8 Mar 24 | Brendan P. Eckelman | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.75 | 2,150 | 76.86 k | 37,850 |
News
Inhibrx Q4 2023 GAAP EPS $(1.73) Misses $(1.04) Estimate, Sales $1.63M Beat $50.00K Estimate
28 Feb 24
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
23 Jan 24
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
23 Jan 24
JMP Securities Downgrades Inhibrx to Market Perform
23 Jan 24
Inhibrx Sells INBRX-101 To Sanofi For Up To $2.2B, Spins Off New Company With All Non-101 Assets And Liabilities
23 Jan 24
Press releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX
28 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, HAYN, EVBG, KAMN
27 Mar 24
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
26 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX
18 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, TAST, MDC, ANSS
16 Mar 24